StockData

Castle Biosciences vs Veracyte

CSTL and VCYT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CSTL and VCYT compare

Veracyte is the larger company, worth 1.9 times as much as Castle Biosciences ($2.0B against $1.0B).

Veracyte grew revenue faster over the last twelve months (17.5% versus 9.8% for Castle Biosciences).

Veracyte keeps more of each dollar of sales as profit, with a net margin of 21.8% compared with −6.1% at Castle Biosciences.

Veracyte scores higher on the StockData Score (17 against 11 for Castle Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCSTLVCYT
Size and price
Market cap$1.0B$2.0B
Share price$33.79$24.33
Change, 1 year−3.0%−42.5%
Change, 5 years−28.9%−50.6%
Beta (5Y)1.381.78
Employees883755
StockData Score
Total score1117 (better)
Valuation score24 (better)
Growth score24 (better)
Performance score33
Health score46 (better)
Dividend score00
Valuation
P/E–15.8×
P/S2.7× (better)3.4×
P/B2.2×1.4× (better)
EV/EBITDA–14.5×
P/FCF260×12.1× (better)
FCF yield0.38%8.3% (better)
Fair value$34.71$36.85
Margin of safety2.6%34.0% (better)
Growth
Revenue growth (TTM)9.8%17.5% (better)
Revenue growth, 5Y average40.6% (better)34.5%
Net income growth (TTM)–318%
EPS growth (TTM)–305%
Profitability
Gross margin77.1% (better)72.0%
Operating margin−7.4%17.1% (better)
Net margin−6.1%21.8% (better)
FCF margin1.1%27.8% (better)
Return on equity−4.9%9.4% (better)
Return on invested capital−11.1%9.1% (better)
Financial health
Debt / equity0.02 (better)0.00
Interest coverage−51.2×–
Current ratio5.285.56 (better)
Altman Z-score6.638.99 (better)
Piotroski F-score47 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions89.5%111%
Held by insiders1.9%1.7%
Insider net buying, 12 months−$18.3M (better)−$18.6M
Short interest, % of float7.0%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.